AC Immune SA FCF yield
What is the FCF yield of AC Immune SA?
The FCF yield of AC Immune SA is -55.97%
What is the definition of FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield of companies in the Health Care sector on NASDAQ compared to AC Immune SA
What does AC Immune SA do?
ac immune is a clinical-stage swiss-based biopharmaceutical company, listed on nasdaq, which aims to become a global leader in precision medicine for neurodegenerative diseases. the company designs, discovers and develops therapeutic as well as diagnostic products intended to prevent and modify diseases caused by misfolding proteins. ac immune’s two proprietary technology platforms create antibodies, small molecules and vaccines designed to address a broad spectrum of neurodegenerative indications, such as alzheimer’s disease (ad). the company’s pipeline features nine therapeutic and three diagnostic product candidates – with five product candidates currently in clinical trials. the most advanced of these is crenezumab, a humanized anti-amyloid-β monoclonal igg4 antibody that targets monomeric and aggregated forms of amyloid-β, with highest affinity for neurotoxic oligomers. crenezumab is currently in two phase 3 clinical studies for ad, under a global program conducted by the collabor
Companies with fcf yield similar to AC Immune SA
- Leveljump Healthcare has FCF yield of -56.23%
- Organic Garage has FCF yield of -56.17%
- China Power International Development has FCF yield of -56.16%
- Kintara Therapeutics has FCF yield of -56.10%
- Helix Resources has FCF yield of -56.06%
- ENDRA Life Sciences Inc has FCF yield of -56.05%
- AC Immune SA has FCF yield of -55.97%
- Universal Copper has FCF yield of -55.95%
- Marathon Gold has FCF yield of -55.93%
- Rex Resources has FCF yield of -55.92%
- InMed Pharmaceuticals has FCF yield of -55.87%
- Surge Battery Metals has FCF yield of -55.83%
- Pressure BioSciences has FCF yield of -55.71%